{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T16:48:27Z","timestamp":1756572507305,"version":"3.44.0"},"reference-count":49,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRR"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Juvenile-onset systemic lupus erythematosus (jSLE) is an uncommon yet severe autoimmune\/inflammatory condition affecting multiple bodily systems, typically manifest-ing before the age of 18. This disease exhibits significant complexity, displaying considerable variation among patients. Its effects can range in severity from minor to fatal, characterized by a pattern of recurring flare-ups and periods of remission, making its natural progression difficult to predict.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Aim of the Work:<\/jats:title>\n<jats:p>The aim of this work is to investigate the correlation between semaphorin 3A and systemic lupus erythematosus patients who follow up at Pediatric Rheumatology Unit Chil-dren's Hospital at Cairo University.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Patients &amp; Methods:<\/jats:title>\n<jats:p>This cross-sectional research was performed at the Pediatric Rheumatology Unit Cairo University Children's Hospital and included cases with jSLE under treatment and fol-low-up from the period of August 2021 to August 2022.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Regarding demographic data of the studied subjects, highly significant variances were\nnoted among the patient group and control group regarding age (years) and sex. However, there\nwere non-significant variances among the patient group and control group concerning weight.\nIn the current research, median (IQR) onset of disease was 2 (1-3) years, mean \u00b1 SD age at disease\ndiagnosis was 8.98 \u00b1 2.13 years, median (IQR) disease duration 2 (1-3) years, family history\nwas negative in 36 (90.0%) patients and consanguinity was negative in 28 (70.0%).\nThe distribution of the manifestations within the patients group was as follows 7 (17.5%) with\nmucocutaneous, 7 (17.5%) with vasculitis, 4 (10.0%) with serositis, 11 (27.5%) with cardiac, 17\n(42.5%) with renal, 11 (27.5%) with GIT, 5 (12.5%) with hematological, and 4 (10.0%) with neurological\nmanifestations. In addition, there were 2 (5.0%) with arthritis, 31 (77.5%) with arthralgia,\nand 2 (5.0%) with fever, mean \u00b1 SD systolic BP was 115.95 \u00b1 8.38 and mean \u00b1 SD diastolic\nBP was 75.60 \u00b1 6.11.\nRegarding treatments in the patients\u2019 group, the median steroid dose was 15 mg (5-25) with median\nduration of 2 (1-3), 38 (95.0%) patients received hydroxychloroquine with mean \u00b1 SD hydroxychloroquine\ndose of 205.26 mg \u00b1 51.71. 23 (57.5%) patients received cyclophosphamide\nwith mean \u00b1 SD number of cyclophosphamide doses 7.17 mg \u00b1 2.42. Mycophenolate was received\nin 27 (67.5%) with mean \u00b1 SD dose of 614.07 mg \u00b1 225.85.\nThere were highly statistically significant differences between control group and patients\u2019 group\nconcerning TLC, creatinine, and ESR. Highly statistically significant variance was noted among\nthe control group and patients group concerning CRP.\nRegarding the patients' group, the mean \u00b1 SD serum C3 was 99.89 mg\/dl \u00b1 28.45, median (IQR)\nserum C4 was 14.5 mg\/dl (8.8-25.5), and median (IQR) albumin creatinine ratio was 27 IU\/ML\n(16-186). There was positive ANA with titre and pattern in 34 patients (85.0%), positive antids-\nDNA in 25 patients (62.5%), and positive anticardiolipin IgM and IgG in 5 patients (12.5%).\nRenal biopsy was found to be normal in 23 (57.5%), lupus nephritis class II, III in 3 (7.5 percent),\nlupus nephritis class III in 10 (25.0%), and lupus nephritis class IV in 4 (10.0%). Urine analysis\nresults showed the following: normal in 28 (70.0%), albumin in 2 (5.0%), casts in 2 (5.0%), pus\ncell in 4 (10.0%), albumin + casts in 2 (5.0%) and albumin + pus cell in 2 (5.0%).\nRegarding semaphorin 3A level, a highly statistically significant variance was noted among the\ncontrol and patients group concerning semaphorin 3A level found to be lower in cases than control with a p-value below 0.001. In patients\u2019 group, a negative correlation for semaphorin 3A with\nSBP, DBP, AST and ESR and also a positive correlation with steroid duration in the studied patients\nwas noted. In addition, highly significant association between semaphorin 3A and positive\nCRP was also observed. However, no significant relationship between semaphorin 3A and SLE\nmanifestations except arthritis was found related to semaphorin 3A level.\nROC curve shows that the semaphorin 3A cut-off point to predict SLE \u2264 3 with sensitivity =\n47.50, specificity=92.50, PPV=86.4, and NPV=63.8.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Reduced plasma Semaphorin 3A levels were found in this study; furthermore, their clinical relationship in SLE proposes their significant job in this illness. Furthermore, the ROC results demonstrated that Semaphorin 3A could be a new symptomatic biomarker in SLE with very high sensitivity for the determination of SLE, demonstrating that they might be helpful bi-omarkers for the evaluation of SLE. However, extra studies that focus on the potential role of Semaphorin 3A in SLE are needed.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0115733971304540240710094833","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T03:10:44Z","timestamp":1721617844000},"page":"288-309","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Study on Semaphorin 3A Level in Juvenile-onset Systemic Lupus Erythematosus Patients"],"prefix":"10.2174","volume":"21","author":[{"given":"Huda","family":"Marzouk","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, Cairo University, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina Hesham","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, Cairo University, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hend Mohamed Abu","family":"Shady","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, Cairo University, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hussien Tarek Abdelrahman","family":"Sarhan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Misr University\nfor Science and Technology, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0545-6969","authenticated-orcid":true,"given":"Mohamed Salah Eldin Mohamed","family":"AbdelKader","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Misr University\nfor Science and Technology, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"ITC81","DOI":"10.7326\/AITC202006020","volume":"172","author":"Kiriakidou M.","year":"2020","unstructured":"Kiriakidou M.; Ching C.L.; Systemic Lupus Erythematosus. Ann Intern Med  2020,172(11),ITC81-ITC96","journal-title":"Ann Intern Med"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.semarthrit.2008.10.007","volume":"39","author":"Pons-Estel G.J.","year":"2010","unstructured":"Pons-Estel G.J.; Alarcon G.S.; Scofield L.; Reinlib L.; Cooper G.S.; Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum  2010,39,257-268","journal-title":"Semin Arthritis Rheum"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41584-021-00668-1","volume":"17","author":"Barber M.R.W.","year":"2021","unstructured":"Barber M.R.W.; Drenkard C.; Falasinnu T.; Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol  2021,17(9),515-532","journal-title":"Nat Rev Rheumatol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","volume":"80","author":"Fanouriakis A.","year":"2021","unstructured":"Fanouriakis A.; Tziolos N.; Bertsias G.; Boumpas D.T.; Update \u03bfn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis  2021,80(1),14-25","journal-title":"Ann Rheum Dis"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41584-020-00544-4","volume":"17","author":"Fillatreau S.","year":"2021","unstructured":"Fillatreau S.; Manfroi B.; D\u00f6rner T.; Toll-like receptor signalling in B cells during systemic lupus erythematosus. Nat Rev Rheumatol  2021,17(2),98-108","journal-title":"Nat Rev Rheumatol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.7326\/M21-2078","volume":"174","author":"Shipa M.","year":"2021","unstructured":"Shipa M.; Embleton-Thirsk A.; Parvaz M.; Effectiveness of belimumab after rituximab in systemic lupus erythematosus: A randomized controlled trial. Ann Intern Med  2021,174(12),1647-1657","journal-title":"Ann Intern Med"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1177\/0961203317747717","volume":"27","author":"Sahin S.","year":"2018","unstructured":"Sahin S.; Adrovic A.; Barut K.; Juvenile systemic lupus erythematosus in Turkey: Demographic, clinical and laboratory features with disease activity and outcome. Lupus  2018,27(3),514-519","journal-title":"Lupus"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00296-019-04442-1","volume":"40","author":"Poddighe D.","year":"2020","unstructured":"Poddighe D.; Dauyey K.; Macrophage activation syndrome in juvenile dermatomyositis: A systematic review. Rheumatol Int  2020,40(5),695-702","journal-title":"Rheumatol Int"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/01.bor.0000381996.69261.71","volume":"22","author":"Grom A.A.","year":"2010","unstructured":"Grom A.A.; Mellins E.D.; Macrophage activation syndrome: Advances towards understanding pathogenesis. Curr Opin Rheumatol  2010,22(5),561-566","journal-title":"Curr Opin Rheumatol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"681875","DOI":"10.3389\/fmed.2021.681875","volume":"8","author":"Abdirakhmanova A.","year":"2021","unstructured":"Abdirakhmanova A.; Sazonov V.; Mukusheva Z.; Assylbekova M.; Abdukhakimova D.; Poddighe D.; Macrophage activation syndrome in pediatric systemic lupus erythematosus: A systematic review of the diagnostic aspects. Front Med  2021,8,681875","journal-title":"Front Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/art.41937","volume":"74","author":"Izmirly P.M.","year":"2022","unstructured":"Izmirly P.M.; Kim M.Y.; Samanovic M.; Evaluation of immune response and disease status in systemic lupus erythematosus patients following SARS\u2013CoV\u20102 vaccination. Arthritis Rheumatol  2022,74(2),284-294","journal-title":"Arthritis Rheumatol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"e613","DOI":"10.1016\/S2665-9913(21)00221-6","volume":"3","author":"Felten R.","year":"2021","unstructured":"Felten R.; Kawka L.; Dubois M.; Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study. Lancet Rheumatol  2021,3(9),e613-e615","journal-title":"Lancet Rheumatol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00296-021-04972-7","volume":"41","author":"Bartels L.E.","year":"2021","unstructured":"Bartels L.E.; Ammitzb\u00f8ll C.; Andersen J.B.; Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis. Rheumatol Int  2021,41(11),1925-1931","journal-title":"Rheumatol Int"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1189\/jlb.2A1114-534R","volume":"100","author":"Curreli S.","year":"2016","unstructured":"Curreli S.; Wong B.S.; Latinovic O.; Konstantopoulos K.; Stamatos N.M.; Class 3 semaphorins induce F-actin reorganization in human dendritic cells: Role in cell migration. J Leukoc Biol  2016,100(6),1323-1334","journal-title":"J Leukoc Biol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.trsl.2020.12.007","volume":"232","author":"Fernandez-Ruiz R.","year":"2021","unstructured":"Fernandez-Ruiz R.; Paredes J.L.; Niewold T.B.; COVID-19 in patients with systemic lupus erythematosus: Lessons learned from the inflammatory disease. Transl Res  2021,232,13-36","journal-title":"Transl Res"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/acr.20648","volume":"64","author":"Urowitz M.B.","year":"2012","unstructured":"Urowitz M.B.; Gladman D.D.; Iba\u00f1ez D.; Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res  2012,64(1),132-137","journal-title":"Arthritis Care Res"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.21608\/ejpa.2021.58451.1018","volume":"19","author":"Abo-Ali A.","year":"2021","unstructured":"Abo-Ali A.; Abdel-Hafez M.; El-Bendary A.; Abdelnabi H.; Serum interleukins 2 and 10 in juvenile systemic lupus erythematosus: relation to disease activity. Egypt J Pediatr Allergy Immunol  2021,19(2),89-95","journal-title":"Egypt J Pediatr Allergy Immunol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2018.11.001","volume":"96","author":"Fava A.","year":"2019","unstructured":"Fava A.; Petri M.; Systemic lupus erythematosus: Diagnosis and clinical management. J Autoimmun  2019,96,1-13","journal-title":"J Autoimmun"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-6448-2_1","volume":"1493","author":"Alto L.T.","year":"2017","unstructured":"Alto L.T.; Terman J.R.; Semaphorins and their signaling mechanisms. Methods Mol Biol  2017,1493,1-25","journal-title":"Methods Mol Biol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4161\/cam.27752","volume":"8","author":"Xu R.","year":"2014","unstructured":"Xu R.; Semaphorin 3A. Cell Adhes Migr  2014,8(1),5-10","journal-title":"Cell Adhes Migr"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1002\/art.34410","volume":"64","author":"Watson L.","year":"2012","unstructured":"Watson L.; Leone V.; Pilkington C.; Disease activity, severity, and damage in the UK juvenile\u2010onset systemic lupus erythematosus cohort. Arthritis Rheum  2012,64(7),2356-2365","journal-title":"Arthritis Rheum"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1177\/0961203320909156","volume":"29","author":"Massias J.S.","year":"2020","unstructured":"Massias J.S.; Smith E.M.D.; Al-Abadi E.; Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups. Lupus  2020,29(5),474-481","journal-title":"Lupus"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1177\/09612033211043010","volume":"30","author":"Eesa N.N.","year":"2021","unstructured":"Eesa N.N.; Abdel Nabi H.; Owaidy R.E.; Systemic lupus erythematosus children in Egypt: Homeland spectrum amid the global situation. Lupus  2021,30(13),2135-2143","journal-title":"Lupus"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1177\/0961203317751061","volume":"27","author":"Avar P.O.","year":"2018","unstructured":"Avar P.O.; Shan J.; Brunner H.I.; Mitsnefes M.M.; Blood pressure control over time in childhood-onset systemic lupus erythematous. Lupus  2018,27(4),657-664","journal-title":"Lupus"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1177\/0961203318791046","volume":"27","author":"Aggarwal A.","year":"2018","unstructured":"Aggarwal A.; Phatak S.; Srivastava P.; Lawrence A.; Agarwal V.; Misra R.; Outcomes in juvenile onset lupus: Single center cohort from a developing country. Lupus  2018,27(11),1867-1875","journal-title":"Lupus"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3389\/fped.2018.00144","volume":"6","author":"Costagliola G.","year":"2018","unstructured":"Costagliola G.; Mosca M.; Migliorini P.; Consolini R.; Pediatric systemic lupus erythematosus: Learning from longer follow up to adulthood. Front Pediatr  2018,6,144","journal-title":"Front Pediatr"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/0961203309350755","volume":"19","author":"Lu L.J.","year":"2010","unstructured":"Lu L.J.; Wallace D.J.; Ishimori M.L.; Scofield R.H.; Weisman M.H.; Review: Male systemic lupus erythematosus: A review of sex disparities in this disease. Lupus  2010,19(2),119-129","journal-title":"Lupus"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1546-0096-13-1","volume":"13","author":"Chiewchengchol D.","year":"2015","unstructured":"Chiewchengchol D.; Murphy R.; Edwards S.W.; Beresford M.W.; Mucocutaneous manifestations in juvenile-onset systemic lupus erythematosus: A review of literature. Pediatr Rheumatol Online J  2015,13,1","journal-title":"Pediatr Rheumatol Online J"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3389\/fped.2019.00149","volume":"7","author":"Smith E.M.D.","year":"2019","unstructured":"Smith E.M.D.; Lythgoe H.; Hedrich C.M.; Vasculitis in juvenile-onset systemic lupus erythematosus. Front Pediatr  2019,7,149","journal-title":"Front Pediatr"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.pcl.2012.03.007","volume":"59","author":"Levy D.M.","year":"2012","unstructured":"Levy D.M.; Kamphuis S.; Systemic lupus erythematosus in children and adolescents. Pediatr Clin North Am  2012,59(2),345-364","journal-title":"Pediatr Clin North Am"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1177\/0961203318804889","volume":"27","author":"Chang J.C.","year":"2018","unstructured":"Chang J.C.; Xiao R.; Mercer-Rosa L.; Knight A.M.; Weiss P.F.; Child-onset systemic lupus erythematosus is associated with a higher incidence of myopericardial manifestations compared to adult-onset disease. Lupus  2018,27(13),2146-2154","journal-title":"Lupus"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00467-012-2342-2","volume":"28","author":"Sozeri B.","year":"2013","unstructured":"Sozeri B.; Deveci M.; Dincel N.; Mir S.; The early cardiovascular changes in pediatric patients with systemic lupus erythematosus. Pediatr Nephrol  2013,28(3),471-476","journal-title":"Pediatr Nephrol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"871","DOI":"10.4103\/1319-2442.98194","volume":"23","author":"Nandi M.","year":"2012","unstructured":"Nandi M.; Mondal R.; Renal involvement in childhood lupus: A study from Kolkata, India. Saudi J Kidney Dis Transpl  2012,23(4),871-875","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s10067-017-3571-3","volume":"36","author":"S\u00f6nmez H.E.","year":"2017","unstructured":"S\u00f6nmez H.E.; Karhan A.N.; Batu E.D.; Gastrointestinal system manifestations in juvenile systemic lupus erythematosus. Clin Rheumatol  2017,36(7),1521-1526","journal-title":"Clin Rheumatol"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12969-015-0027-7","volume":"13","author":"Sule S.D.","year":"2015","unstructured":"Sule S.D.; Moodalbail D.G.; Burnham J.; Fivush B.; Furth S.L.; Predictors of arthritis in pediatric patients with lupus. Pediatr Rheumatol Online J  2015,13,30","journal-title":"Pediatr Rheumatol Online J"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"772422","DOI":"10.3389\/fped.2022.772422","volume":"10","author":"Chen Y.J.","year":"2022","unstructured":"Chen Y.J.; Lin Y.J.; Guo M.M.H.; Pediatric lupus presenting as pulmonary hypertension, myocarditis, and massive pericardial effusion in an 11-year-old girl: A case report and literature review. Front Pediatr  2022,10,772422","journal-title":"Front Pediatr"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/1479-5876-11-261","volume":"11","author":"Su Y.J.","year":"2013","unstructured":"Su Y.J.; Cheng T.T.; Chen C.J.; The association among leukocyte apoptosis, autoantibodies and disease severity in systemic lupus erythematosus. J Transl Med  2013,11(1),261","journal-title":"J Transl Med"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.3390\/diagnostics12071701","volume":"12","author":"Dossybayeva K.","year":"2022","unstructured":"Dossybayeva K.; Bexeitov Y.; Mukusheva Z.; Analysis of peripheral blood basophils in pediatric systemic lupus erythematosus. Diagnostics  2022,12(7),1701","journal-title":"Diagnostics"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1590\/2175-8239-jbn-2018-0097","volume":"41","author":"Pinheiro S.V.B.","year":"2019","unstructured":"Pinheiro S.V.B.; Dias R.F.; Fabiano R.C.G.; Araujo S.A.; Silva A.C.S.; Pediatric lupus nephritis. J Bras Nefrol  2019,41(2),252-265","journal-title":"J Bras Nefrol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.15537\/smj.2018.10.23625","volume":"39","author":"Attar S.M.","year":"2018","unstructured":"Attar S.M.; Pediatric systemic lupus erythematosus. Retrospective analysis of clinico-laboratory parameters and their association with systemic lupus erythematosus disease activity index score. Saudi Med J  2018,39(10),1060","journal-title":"Saudi Med J"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"232","DOI":"10.4103\/JLP.JLP_171_17","volume":"10","author":"Afzali P.","year":"2018","unstructured":"Afzali P.; Isaeian A.; Sadeghi P.; Complement deficiency in pediatric-onset systemic lupus erythematosus. J Lab Physicians  2018,10(2),232-236","journal-title":"J Lab Physicians"},{"key":"ref=42","first-page":"279","volume":"39","author":"Rodsaward P.","year":"2021","unstructured":"Rodsaward P.; Chottawornsak N.; Suwanchote S.; The clinical significance of antinuclear antibodies and specific autoantibodies in juvenile and adult systemic lupus erythematosus patients. Asian Pac J Allergy Immunol  2021,39(4),279-286","journal-title":"Asian Pac J Allergy Immunol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1177\/0961203312456753","volume":"21","author":"Vadasz Z.","year":"2012","unstructured":"Vadasz Z.; Toubi E.; Semaphorin 3A a marker for disease activity and a potential putative disease-modifying treatment in systemic lupus erythematosus. Lupus  2012,21(12),1266-1270","journal-title":"Lupus"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.joen.2022.01.020","volume":"48","author":"Wang L.","year":"2022","unstructured":"Wang L.; Song Y.; Yi X.; Semaphorin 7A accelerates the inflammatory osteolysis of periapical lesions. J Endod  2022,48(5),641-649.e2","journal-title":"J Endod"},{"key":"ref=45","first-page":"370","volume":"97","author":"Gao H.","year":"2017","unstructured":"Gao H.; Ma X.X.; Guo Q.; Expression and clinical significance of semaphorin 3A in serum and mononuclear cells in patients with systemic lupus erythematosus. Zhonghua Yi Xue Za Zhi  2017,97(5),370-374","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1517\/17530059.2012.715632","volume":"6","author":"Abdel Kader M.S.E.M.","year":"2012","unstructured":"Abdel Kader M.S.E.M.; Abd Elaziz M.M.; Ahmed D.H.; Role of serum anti-C1q antibodies as a biomarker for nephritis activity in pediatric and adolescent Egyptian female patients with SLE. Expert Opin Med Diagn  2012,6(6),489-498","journal-title":"Expert Opin Med Diagn"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.3390\/biomedicines12061244","volume":"12","author":"Raupov R.","year":"2024","unstructured":"Raupov R.; Suspitsin E.; Kalashnikova E.; IFN-I score and rare genetic variants in children with systemic lupus erythematosus. Biomedicines  2024,12(6),1244","journal-title":"Biomedicines"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"968323","DOI":"10.3389\/fmed.2022.968323","volume":"9","author":"Sprow G.","year":"2022","unstructured":"Sprow G.; Dan J.; Merola J.F.; Werth V.P.; Emerging therapies in cutaneous lupus erythematosus. Front Med  2022,9,968323","journal-title":"Front Med"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2217\/imt-2023-0086","volume":"16","author":"Cho Y.M.","year":"2024","unstructured":"Cho Y.M.; Furie R.; The development of litifilimab (BIIB 059) for cutaneous and systemic lupus erythematosus. Immunotherapy  2024,16(1),15-20","journal-title":"Immunotherapy"}],"container-title":["Current Rheumatology Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115733971304540240710094833","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/232020\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115733971304540240710094833","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T06:34:39Z","timestamp":1756362879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/232020\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115733971304540240710094833","relation":{},"ISSN":["1573-3971"],"issn-type":[{"type":"print","value":"1573-3971"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-03-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}